|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
US4364934A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
EP0348458B1
(en)
|
1987-11-30 |
1997-04-09 |
University Of Iowa Research Foundation |
Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
|
EP0425491B1
(en)
|
1988-03-02 |
1994-07-20 |
The Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1989009221A1
(en)
|
1988-03-25 |
1989-10-05 |
University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
WO1991018913A1
(en)
|
1990-06-07 |
1991-12-12 |
City Of Hope |
Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
|
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5864026A
(en)
|
1990-06-11 |
1999-01-26 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5789157A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
KR970002255B1
(ko)
|
1990-06-11 |
1997-02-26 |
넥스스타 파아마슈티컬드, 인크. |
핵산 리간드
|
|
US5650275A
(en)
|
1990-06-11 |
1997-07-22 |
Nexstar Pharmacueticals Inc |
Target detection method using spectroscopically detectable nucleic acid ligands
|
|
US6365730B1
(en)
|
1990-06-19 |
2002-04-02 |
Gene Shears Pty. Limited |
DNA-Armed ribozymes and minizymes
|
|
CA2109602C
(en)
|
1990-07-10 |
2002-10-01 |
Gregory P. Winter |
Methods for producing members of specific binding pairs
|
|
WO1992001806A1
(en)
|
1990-07-16 |
1992-02-06 |
The Public Health Research Institute Of The City Of New York, Inc. |
Selection of ribozymes that efficiently cleave target rna
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
WO1992007065A1
(en)
|
1990-10-12 |
1992-04-30 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified ribozymes
|
|
JPH06504628A
(ja)
|
1990-12-20 |
1994-05-26 |
エクソン・ケミカル・パテンツ・インク |
リソグラフィー及び腐食防止コーティング用途向けのｕｖ／ｅｂ硬化性ブチルコポリマー
|
|
DE69233769D1
(de)
|
1991-03-01 |
2009-09-24 |
Dyax Corp |
Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
|
|
AU662148B2
(en)
|
1991-04-10 |
1995-08-24 |
Scripps Research Institute, The |
Heterodimeric receptor libraries using phagemids
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US6100099A
(en)
|
1994-09-06 |
2000-08-08 |
Abbott Laboratories |
Test strip having a diagonal array of capture spots
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5436143A
(en)
|
1992-12-23 |
1995-07-25 |
Hyman; Edward D. |
Method for enzymatic synthesis of oligonucleotides
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
CN1048254C
(zh)
|
1993-12-09 |
2000-01-12 |
托马斯杰弗逊大学 |
用于将预定的改变引入靶基因中的化合物
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5650502A
(en)
|
1994-11-09 |
1997-07-22 |
Hybridon, Inc. |
Ribozyme analogs having rigid non-nucleotidic linkers
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5693773A
(en)
|
1995-06-07 |
1997-12-02 |
Hybridon Incorporated |
Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
ATE279947T1
(de)
|
1996-03-18 |
2004-11-15 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5989823A
(en)
|
1998-09-18 |
1999-11-23 |
Nexstar Pharmaceuticals, Inc. |
Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
PT1152009E
(pt)
|
1999-02-12 |
2005-03-31 |
Sankyo Co |
Novos analogos de nucleosidos e oligonucleotidos
|
|
US6136603A
(en)
|
1999-03-26 |
2000-10-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of interleukin-5 signal transduction
|
|
US6569630B1
(en)
|
1999-07-02 |
2003-05-27 |
Conceptual Mindworks, Inc. |
Methods and compositions for aptamers against anthrax
|
|
US7064142B2
(en)
|
2000-02-22 |
2006-06-20 |
Banyu Pharmaceutical, Co., Ltd. |
Imidazonline compounds
|
|
WO2001083740A2
(en)
|
2000-05-04 |
2001-11-08 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
EP1518120A4
(en)
|
2002-03-11 |
2008-08-13 |
Momenta Pharmaceuticals Inc |
ANALYSIS OF SULFATE POLYSACCHARIDES
|
|
AU2003239897A1
(en)
|
2002-05-23 |
2003-12-12 |
Ceptyr, Inc. |
Modulation of ptp1b signal transduction by rna interference
|
|
JP2006507841A
(ja)
|
2002-11-14 |
2006-03-09 |
ダーマコン， インコーポレイテッド |
機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
US7902160B2
(en)
|
2002-11-25 |
2011-03-08 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
|
EP1572660B1
(en)
|
2002-12-20 |
2011-01-26 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
CA2515623A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
WO2004094647A2
(en)
|
2003-04-18 |
2004-11-04 |
Cytovia, Inc. |
Methods of treating diseases responsive to induction of apoptosis and screening assays
|
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
|
MXPA06000619A
(es)
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
|
|
EP2530157B1
(en)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
|
CA2553955C
(en)
|
2004-02-10 |
2012-08-28 |
Zystor Therapeutics, Inc. |
Acid alpha-glucosidase and fragments thereof
|
|
WO2005087217A1
(en)
|
2004-03-05 |
2005-09-22 |
The General Hospital Corporation |
Compositions and methods for modulating interaction between polypeptides
|
|
WO2005113571A2
(en)
|
2004-05-13 |
2005-12-01 |
The University Of North Carolina At Chapel Hill |
Methods for the delivery of oligomeric compounds
|
|
WO2005111211A2
(en)
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
EP1812031B1
(en)
|
2004-11-01 |
2015-06-24 |
The Regents of the University of California |
Compositions and methods for modification of biomolecules
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
US20060252107A1
(en)
|
2005-02-22 |
2006-11-09 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
JP2009511023A
(ja)
|
2005-10-06 |
2009-03-19 |
ユニバーシティー、オブ、デラウェア |
ハンチントン病の治療のためのｇに富むポリヌクレオチド
|
|
JP2007104971A
(ja)
|
2005-10-14 |
2007-04-26 |
New Industry Research Organization |
ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
ES2351674T3
(es)
|
2006-01-27 |
2011-02-09 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
|
|
WO2007089612A2
(en)
|
2006-01-30 |
2007-08-09 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing bacterial infections
|
|
MX361816B
(es)
|
2006-02-09 |
2018-12-17 |
Genzyme Corp |
Suministro intraventricular lento.
|
|
WO2008029281A2
(en)
|
2006-02-10 |
2008-03-13 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
DK2666859T3
(en)
|
2006-04-03 |
2019-04-08 |
Roche Innovation Ct Copenhagen As |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
DK2021472T3
(da)
|
2006-05-05 |
2011-09-19 |
Isis Pharmaceuticals Inc |
Forbindelser og fremgangsmåder til modulering af genekspression
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
EP2076597A2
(en)
|
2006-10-09 |
2009-07-08 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of pcsk9
|
|
CA2667055C
(en)
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
ES2569365T3
(es)
|
2006-11-29 |
2016-05-10 |
Nationwide Children's Hospital |
Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
|
|
CN102978185B
(zh)
|
2007-01-18 |
2015-02-11 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
|
US8318438B2
(en)
|
2007-03-01 |
2012-11-27 |
The United States Of America As Represented By The Secretary Of The Air Force |
Aptamer-based assays
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
CN101801413A
(zh)
|
2007-07-12 |
2010-08-11 |
托勒克斯股份有限公司 |
采用gitr结合分子的联合疗法
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2203173B1
(en)
|
2007-10-26 |
2015-12-23 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US9050333B2
(en)
|
2008-07-08 |
2015-06-09 |
Duke University |
Method of treating glycogen storage disease type III with human acid α-glucosidase
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
PT2344637E
(pt)
|
2008-10-27 |
2015-03-23 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
PL2889043T3
(pl)
|
2008-12-16 |
2019-09-30 |
Genzyme Corporation |
Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
|
|
US8466340B2
(en)
|
2009-02-18 |
2013-06-18 |
Amicus Therapeutics, Inc. |
Mouse model for pompe disease and methods of use thereof
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
EP2475376B1
(en)
|
2009-06-17 |
2016-03-30 |
BioMarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
BR122023023194A2
(pt)
|
2009-11-12 |
2023-12-26 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição e respectivo uso
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP2894142B1
(en)
|
2010-04-27 |
2019-06-12 |
SynAffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
KR102182663B1
(ko)
|
2010-05-28 |
2020-11-25 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
JP5913307B2
(ja)
|
2010-07-12 |
2016-04-27 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
多機能性抗体複合体
|
|
EP3489360A3
(en)
|
2010-07-19 |
2019-08-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
EP2606152B2
(en)
|
2010-08-18 |
2025-03-12 |
Fred Hutchinson Cancer Center |
Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP2426203B1
(en)
|
2010-09-02 |
2016-07-13 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
WO2012075037A1
(en)
|
2010-11-30 |
2012-06-07 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
CA2826836A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
|
EP3067421B1
(en)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
CA2833223A1
(en)
|
2011-04-22 |
2012-10-26 |
Prosensa Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
|
|
CN107080847A
(zh)
|
2011-06-24 |
2017-08-22 |
森彻斯有限公司 |
细胞外靶向药物缀合物
|
|
AU2012286994B2
(en)
|
2011-07-25 |
2017-08-10 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of DUX4
|
|
US20140242093A1
(en)
|
2011-07-29 |
2014-08-28 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
|
CA2858347C
(en)
|
2011-12-05 |
2020-07-07 |
New York University |
V1v2 immunogens
|
|
EP2788087A4
(en)
|
2011-12-06 |
2015-08-26 |
Ohio State Innovation Foundation |
Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases
|
|
CA3132111A1
(en)
|
2011-12-28 |
2013-07-04 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
|
|
US20130177579A1
(en)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
CN118581086A
(zh)
|
2012-01-27 |
2024-09-03 |
比奥马林技术公司 |
用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
WO2013120038A2
(en)
|
2012-02-10 |
2013-08-15 |
Regents Of The University Of Minnesota |
Morpholino targeting dux4 for treating fshd
|
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
|
JP6194324B2
(ja)
|
2012-03-15 |
2017-09-06 |
オキシレイン ユーケー リミテッド |
ポンペ病の処置のための方法および材料
|
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
|
EP3604536B1
(en)
|
2012-04-23 |
2024-05-29 |
Vico Therapeutics B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
ES2791778T3
(es)
|
2012-08-01 |
2020-11-05 |
Ikaika Therapeutics Llc |
Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
KR102240217B1
(ko)
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
ES2659270T5
(en)
|
2012-10-23 |
2026-02-11 |
Synaffix Bv |
Modified antibody, antibody-conjugate and process for the preparation thereof
|
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
HRP20190382T1
(hr)
|
2013-03-14 |
2019-04-19 |
Sarepta Therapeutics, Inc. |
Pripravci koji preskaču ekson za liječenje mišićne distrofije
|
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
WO2014189370A1
(en)
|
2013-05-24 |
2014-11-27 |
Stichting Katholieke Universiteit |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
ES3029138T3
(en)
|
2013-06-05 |
2025-06-23 |
Univ Duke |
Rna-guided gene editing and gene regulation
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
WO2015023937A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
|
WO2015023939A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
RU2016111137A
(ru)
|
2013-08-28 |
2017-10-03 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Сконструированные конъюгаты против dll3 и способы применения
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
|
CA2929574A1
(en)
|
2013-11-11 |
2015-05-14 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
EP3450557A1
(en)
|
2013-12-25 |
2019-03-06 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
|
EP3097079B1
(en)
|
2014-01-24 |
2021-05-12 |
SynAffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
WO2015112016A1
(en)
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
WO2015134365A2
(en)
|
2014-03-03 |
2015-09-11 |
Acharjee Sujata |
Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies
|
|
RU2730681C2
(ru)
|
2014-03-12 |
2020-08-24 |
Ниппон Синяку Ко., Лтд. |
Антисмысловые нуклеиновые кислоты
|
|
WO2015143062A1
(en)
|
2014-03-18 |
2015-09-24 |
Fred Hutchinson Cancer Research Center |
Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd)
|
|
US10240509B2
(en)
|
2014-04-25 |
2019-03-26 |
Yamaha Motor Power Products Kabushiki Kaisha |
Engine
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
EP3146050B1
(en)
|
2014-05-23 |
2020-08-12 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
AU2015277924B2
(en)
|
2014-06-17 |
2021-02-25 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acids
|
|
KR20170030648A
(ko)
|
2014-08-04 |
2017-03-17 |
시나픽스 비.브이. |
베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법
|
|
US9752144B2
(en)
|
2014-08-04 |
2017-09-05 |
MiRagen Therapeutics, Inc. |
Inhibitors of MYH7B and uses thereof
|
|
MX2017001898A
(es)
|
2014-08-11 |
2017-04-11 |
Shire Human Genetic Therapies |
Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CN114540327B
(zh)
|
2014-09-30 |
2026-03-24 |
阿米库斯治疗学公司 |
具有增强的碳水化合物的高强度酸性α-葡糖苷酶
|
|
ES2740907T3
(es)
|
2014-10-03 |
2020-02-07 |
Synaffix Bv |
Enlazador de sulfamida, conjugados de los mismos y métodos de preparación
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
PH12017500935A1
(en)
|
2014-11-21 |
2017-11-27 |
Merck Sharp & Dohme |
Insulin receptor partial agonists
|
|
US20190002876A1
(en)
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
CA2977528A1
(en)
|
2015-02-27 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
HUE038511T2
(hu)
|
2015-04-23 |
2018-10-29 |
Synaffix Bv |
(1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás
|
|
IL310251A
(en)
|
2015-05-04 |
2024-03-01 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
|
|
CN114681621B
(zh)
|
2015-05-19 |
2024-08-06 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
|
KR20250073514A
(ko)
|
2015-06-24 |
2025-05-27 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
|
|
EP3325509B1
(en)
|
2015-07-22 |
2020-12-16 |
Inatherys |
Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
|
|
HRP20201125T1
(hr)
|
2015-09-15 |
2020-10-30 |
Nippon Shinyaku Co., Ltd. |
Antisens nukleinska kiselina
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
US20180237775A1
(en)
|
2015-09-21 |
2018-08-23 |
Association Institut De Myologie |
Antisense oligonucleotides and uses thereof
|
|
US20180265859A1
(en)
|
2015-09-23 |
2018-09-20 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
EP3359523A4
(en)
|
2015-10-09 |
2019-07-24 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
|
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
PE20181156A1
(es)
|
2015-11-05 |
2018-07-19 |
Bamboo Therapeutics Inc |
Genes de ataxia de friedreich modificados y vectores para terapia genica
|
|
KR20250133801A
(ko)
|
2015-12-08 |
2025-09-08 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화 조성물 및 방법
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
MX2018007451A
(es)
|
2015-12-18 |
2018-11-09 |
Eisai R&D Man Co Ltd |
Inmunoglobulinas conjugadas con lisina c-terminal.
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
IL260983B
(en)
|
2016-02-19 |
2022-07-01 |
Genisphere Llc |
Nucleic acid carriers and methods of medical use
|
|
JP7046003B2
(ja)
|
2016-03-30 |
2022-04-01 |
アミカス セラピューティックス インコーポレイテッド |
高ｍ６ｐ組換えタンパク質の選択方法
|
|
SG11201808455VA
(en)
|
2016-03-30 |
2018-10-30 |
Amicus Therapeutics Inc |
Formulations comprising recombinant acid alpha-glucosidase
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
WO2017173411A1
(en)
|
2016-04-02 |
2017-10-05 |
Research Institute At Nation Wide Children's Hospital |
Modified u6 promoter system for tissue specific expression
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
MY200252A
(en)
|
2016-04-18 |
2023-12-16 |
Sarepta Therapeutics Inc |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
US20190249173A1
(en)
|
2016-05-04 |
2019-08-15 |
Chandra Vargeese |
Methods and compositions of biologically active agents
|
|
EP3922260A3
(en)
|
2016-05-24 |
2022-06-15 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
US20190240346A1
(en)
|
2016-06-20 |
2019-08-08 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
WO2018002812A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
|
US20180028554A1
(en)
|
2016-07-05 |
2018-02-01 |
Biomarin Technologies B.V. |
Oligomers Having Bicyclic Scaffold Moeities
|
|
US20190330626A1
(en)
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
PE20191203A1
(es)
|
2016-09-12 |
2019-09-10 |
Genethon |
Variantes de alfa-glucosidasa acida y usos de las mismas
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3516062A1
(en)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Myostatin irna compositions and methods of use thereof
|
|
MX2019005671A
(es)
|
2016-11-16 |
2020-07-20 |
Academisch Ziekenhuis Leiden |
Sustancias para direccionar diversos organos o tejidos seleccionados.
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
CN110382695A
(zh)
|
2016-11-28 |
2019-10-25 |
得克萨斯州大学系统董事会 |
通过crispr/cpf1介导的基因编辑来预防肌营养不良
|
|
WO2018107003A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
CN117298290A
(zh)
|
2016-12-19 |
2023-12-29 |
萨勒普塔医疗公司 |
用于肌肉萎缩症的外显子跳跃寡聚体缀合物
|
|
NZ752703A
(en)
|
2016-12-26 |
2022-09-30 |
Japan Chem Res |
Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
|
US10940185B2
(en)
|
2016-12-28 |
2021-03-09 |
Jcr Pharmaceuticals Co., Ltd. |
Lyophilized preparation
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
CN110381980A
(zh)
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
|
EP3574018A4
(en)
|
2017-01-27 |
2020-10-07 |
Silverback Therapeutics, Inc. |
CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
|
|
ES3065816T3
(en)
|
2017-06-07 |
2026-05-08 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
CA3099522C
(en)
|
2017-09-19 |
2024-10-08 |
The Governors Of The University Of Alberta |
GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY
|
|
MA50269A
(fr)
|
2017-09-22 |
2020-07-29 |
Avidity Biosciences Inc |
Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3668997A4
(en)
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
US11110180B2
(en)
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
|
US20210032622A1
(en)
|
2017-11-09 |
2021-02-04 |
Crispr Therapeutics Ag |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
EP3720504A1
(en)
|
2017-12-06 |
2020-10-14 |
Synaffix B.V. |
Enediyne conjugates
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
WO2019136180A2
(en)
|
2018-01-04 |
2019-07-11 |
Avidity Biosciences Llc |
Heteroduplex nucleic acid molecules and uses thereof
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
KR20200116933A
(ko)
|
2018-01-31 |
2020-10-13 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
인간 심근세포에서 디스트로핀 돌연변이를 교정하기 위한 조성물 및 방법
|
|
WO2019152820A1
(en)
|
2018-02-02 |
2019-08-08 |
Fred Hutchinson Cancer Research Center |
Methods for treating facioscapulohumeral muscular dystrophy
|
|
SG11202006433PA
(en)
|
2018-02-05 |
2020-08-28 |
Jcr Pharmaceuticals Co Ltd |
Method for delivering drug to muscle
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
IL277889B2
(en)
|
2018-04-12 |
2025-01-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods of using them
|
|
EP3784248A4
(en)
|
2018-04-26 |
2022-08-10 |
Sarepta Therapeutics, Inc. |
EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
SG11202010841QA
(en)
|
2018-05-11 |
2020-11-27 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
SG11202010131QA
(en)
|
2018-05-11 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
JP2021526796A
(ja)
|
2018-06-13 |
2021-10-11 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマー
|
|
WO2019246480A1
(en)
|
2018-06-21 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
US20220378934A1
(en)
|
2018-08-02 |
2022-12-01 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
EA202190418A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
|
|
MX2021001282A
(es)
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos al músculo y sus usos.
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP7611825B2
(ja)
|
2018-08-02 |
2025-01-10 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
CA3108287A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US20210308274A1
(en)
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3108285A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
WO2020047282A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Copenhagen |
Lysosomal enzymes modified by cell based glycoengineering
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
WO2020094670A1
(en)
|
2018-11-05 |
2020-05-14 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
CN113383078A
(zh)
|
2018-12-06 |
2021-09-10 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
AU2019419494B2
(en)
|
2018-12-31 |
2026-03-26 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
|
SG11202108757XA
(en)
|
2019-03-28 |
2021-10-28 |
Sarepta Therapeutics Inc |
Methods for treating muscular dystrophy with casimersen
|
|
WO2020209285A1
(ja)
|
2019-04-08 |
2020-10-15 |
国立大学法人東京医科歯科大学 |
筋疾患治療用医薬組成物
|
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
CA3137715A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
CA3142283A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
CN114025805B
(zh)
|
2019-06-07 |
2025-01-24 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
WO2021003573A1
(en)
|
2019-07-09 |
2021-01-14 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
WO2021076856A1
(en)
|
2019-10-18 |
2021-04-22 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2021108640A1
(en)
|
2019-11-27 |
2021-06-03 |
Dtx Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
PE20221266A1
(es)
|
2019-12-20 |
2022-08-16 |
Codexis Inc |
Variantes de alfa-glucosidasa acida disenadas por ingenieria
|
|
US20230088865A1
(en)
|
2020-01-10 |
2023-03-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
IL294479A
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
|
|
KR20220125802A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
CN115335062A
(zh)
|
2020-01-10 |
2022-11-11 |
达因疗法公司 |
肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
EP4093773A4
(en)
|
2020-01-24 |
2024-02-28 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USE FOR THE TREATMENT OF MUSCLE ATROPHY
|
|
US12624120B2
(en)
|
2020-01-31 |
2026-05-12 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TfR) antibody and uses thereof
|
|
WO2021154476A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
WO2022020105A1
(en)
|
2020-07-23 |
2022-01-27 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US20230285586A1
(en)
|
2020-07-23 |
2023-09-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
IL299663A
(en)
|
2020-07-23 |
2023-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
|
|
CN116348139A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
US20230346966A1
(en)
|
2020-07-23 |
2023-11-02 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
CA3189861A1
(en)
|
2020-09-01 |
2022-03-10 |
Sean Christopher DAUGHERTY |
Dux4 inhibitors and methods of use thereof
|
|
EP4208173A4
(en)
|
2020-09-03 |
2025-11-26 |
Dyne Therapeutics Inc |
PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
JP2023551279A
(ja)
|
2020-11-30 |
2023-12-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
顔面肩甲上腕筋ジストロフィー（ｆｓｈｄ）を治療するための組成物及び方法
|
|
US20240100177A1
(en)
|
2020-12-04 |
2024-03-28 |
Dyne Therapeutics, Inc. |
Antibody-oligonucleotide complexes and uses thereof
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3202826A1
(en)
|
2020-12-31 |
2022-07-07 |
Duncan Brown |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2024504377A
(ja)
|
2021-01-22 |
2024-01-31 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｄｕｘ４の発現を低減するための化合物及び方法
|
|
US20250243244A1
(en)
|
2021-03-31 |
2025-07-31 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
US20250302979A1
(en)
|
2021-04-02 |
2025-10-02 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
CA3216839A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
EP4359008A4
(en)
|
2021-06-21 |
2026-05-06 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USE TO TREAT FRIEDREICH'S ATAXIA
|
|
EP4359534A1
(en)
|
2021-06-21 |
2024-05-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
AU2022298028A1
(en)
|
2021-06-23 |
2023-12-21 |
National Center Of Neurology And Psychiatry |
Combination of antisense oligomers
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2024000494A
(es)
|
2021-07-09 |
2024-04-10 |
Dyne Therapeutics Inc |
Complejos dirigidos al tratamiento de musculos, y usos de los mismos para tratar distrofinopatías.
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
WO2023283619A2
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US20240382513A1
(en)
|
2021-07-09 |
2024-11-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2023283615A1
(en)
|
2021-07-09 |
2023-01-12 |
Dynetherapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL309909A
(en)
|
2021-07-09 |
2024-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
KR20240035824A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
CN117980006A
(zh)
|
2021-07-09 |
2024-05-03 |
达因疗法公司 |
用于治疗肌养蛋白病的肌肉靶向复合物和制剂
|
|
WO2023022229A1
(ja)
|
2021-08-19 |
2023-02-23 |
国立大学法人東京医科歯科大学 |
モルホリノ核酸を含む修飾ヘテロ核酸
|
|
US20240390508A1
(en)
|
2021-08-21 |
2024-11-28 |
Takeda Pharmaceutical Company Limited |
Human transferrin receptor binding peptide-drug conjugate
|
|
JP2024532465A
(ja)
|
2021-09-01 |
2024-09-05 |
エントラーダ セラピューティクス，インコーポレイティド |
デュシェンヌ型筋ジストロフィーにおいてエクソン４５をスキッピングするための組成物及び方法
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
AU2022345986A1
(en)
|
2021-09-16 |
2024-03-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating dystrophinopathies
|
|
CN118201640A
(zh)
|
2021-11-01 |
2024-06-14 |
达因疗法公司 |
用于治疗肌养蛋白病的肌肉靶向复合物
|
|
WO2023086864A1
(en)
|
2021-11-12 |
2023-05-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
US20250250564A2
(en)
|
2021-12-22 |
2025-08-07 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
IL313731A
(en)
|
2021-12-22 |
2024-08-01 |
Sapreme Tech Bv |
Preparations containing nucleic acids and sponges aimed at treating muscle wasting diseases
|
|
KR20240121778A
(ko)
|
2021-12-22 |
2024-08-09 |
사프렘 테크놀로지스 비.브이. |
근육 소모 장애의 치료를 위한 표적화된 사포닌-핵산 접합체
|
|
US20250114464A1
(en)
|
2022-01-27 |
2025-04-10 |
The Governors Of The University Of Alberta |
Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
US20250170259A1
(en)
|
2022-03-03 |
2025-05-29 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
JP2025509438A
(ja)
|
2022-03-17 |
2025-04-11 |
サレプタ セラピューティクス， インコーポレイテッド |
ホスホロジアミデートモルホリノオリゴマーコンジュゲート
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
KR20250004770A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
|
|
EP4508091A1
(en)
|
2022-04-15 |
2025-02-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20250249117A1
(en)
|
2022-04-15 |
2025-08-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating myotonic dystrophy
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
IL317868A
(en)
|
2022-07-06 |
2025-02-01 |
Dyne Therapeutics Inc |
CNS targeting complexes and their uses
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2025533454A
(ja)
|
2022-09-21 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
|
|
KR20250099717A
(ko)
|
2022-10-31 |
2025-07-02 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 dmd 유전자의 엑손 45를 스키핑하기 위한 그의 용도
|
|
WO2024112809A2
(en)
|
2022-11-21 |
2024-05-30 |
Pepgen Inc. |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
TW202440925A
(zh)
|
2023-01-10 |
2024-10-16 |
美商浩博生物醫藥有限公司 |
供使用之經修飾之多段式反義寡核苷酸
|
|
KR20250159196A
(ko)
|
2023-02-27 |
2025-11-10 |
다인 세라퓨틱스, 인크. |
근육내 섬유증의 진행을 억제하기 위한 방법 및 조성물
|